EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.

View source ↗

Summary

EMA authorizes Padcev (enfortumab vedotin) for specified urologic carcinoma indications, marking an official market approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Transitional Cell
• Urologic Neoplasms

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Urologic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 16/07/2026